G-CSF is a key modulator of MDSC and could be a potential therapeutic target in colitisassociated colorectal cancers

Abstract

Granulocyte colony-stimulating factor (G-CSF) is an essential regulator of neutrophil trafficking and is highly expressed in multiple tumors. Myeloid derived suppressor cells (MDSCs) promote neoplastic progression through multiple mechanisms by immune suppression.Despite the findings of G-CSF function in colon cancer progression, the precise mechanism of G-CSF on MDSCs regulation and its blockade effects on tumor growth remains a worthy area of investigation. In this study we observed an overexpression of G-CSF in a mouse colitis-associated cancer (CAC) model, which was consistent with the accumulation of MDSCs in mouse colon tissues. Further in vitro studies demonstrated that G-CSF could promote MDSCs survival and activation through signal transducer and activator of transcription 3 (STAT3) signaling pathway. Moreover,compared with isotype control, anti-G-CSF mAb treatment demonstrated reduced MDSC accumulation, which led to a marked decrease in neoplasm size and number in mice. Our results indicated that G-CSF is a critical regulating molecule in the migration, proliferation and function maintenance of MDSCs, which could be a potential therapeutic target for colitis-associated cancer.

Keywords

inflammation / cancer / granulocyte colonystimulating factor / myeloid derived suppressor cells

References

[1] Abrams SI,Waight JD (2012) Identification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression. Oncoimmunology 1:550–551

[2] Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH (2012)Tumor-derivedgranulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21:822–835

[3] Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP, Zanovello P(2000) Identification of a CD11b(+)/Gr-1 (+)/CD31(+) myeloid progenitor capable of activating or sup¬pressing CD8(+)Tcells. Blood 96:3838–3846

[4] Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67:10019–10026

[5] Candido J, Hagemann T(2013) Cancer-relatedinflammation. JC lin Immunol 33(Suppl 1):S79–S84

[6] Chakraborty A, Guha S (2007) Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells. Urology 69:1210–1215

[7] Condamine T, Ramachandran I, Youn JI, Gabrilovich DI (2015) Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med 66:97–110

[8] Filipazzi P, Huber V, Rivoltini L (2012) Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 61:255–263

[9] Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174

[10] Gallimore AM, Godkin A (2013) Epithelial barriers, microbiota, and colorectal cancer. N EnglJ Med 368:282–284

[11] Gordon S, Taylor PR (2005) Monocyte and macrophage hetero-geneity. Nat Rev Immunol 5:953–964

[12] Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung KE et al (2012) Adenoma-linked barrier defects and microbial products drive IL–23/IL-17-mediated tumour growth. Nature 491:254–258

[13] Kortylewski M, Kujawski M,Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mule J, Kerr WG et al (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11:1314–1321

[14] Kusmartsev S, Nefedova Y,Yoder D, Gabrilovich DI (2004) Antigen-specific inhibitionofCD8+Tcell responseby immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172:989–999

[15] Li Q, Pan PY, Gu P,Xu D, Chen SH (2004) Roleof immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res 64:1130–1139

[16] Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C, Fowler KJ, Basu S, Zhan YF, Dunn AR (1994) Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84:1737–1746

[17] Liongue C, Wright C, Russell AP, Ward AC (2009) Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. IntJ Biochem Cell Biol 41:2372–2375

[18] Morris KT, Khan H, Ahmad A, Weston LL, Nofchissey RA, Pinchuk IV, Beswick EJ (2014) G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration. BrJ Cancer 110:1211–1220

[19] Morris KT, Castillo EF, Ray AL, Weston LL, Nofchissey RA, Hanson JA, Samedi VG, Pinchuk IV, Hudson LG, Beswick EJ (2015) Anti-G-CSF treatment induces protective tumor immunity in mouse colon cancerby promoting protectiveNK cell, macrophage andT cell responses. Oncotarget 6(26):22338–22347

[20] Natori T, Sata M, Washida M, Hirata Y, Nagai R, Makuuchi M(2002) G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 297:1058–1061

[21] Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI (2005) Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 65:9525–9535

[22] Savarese TM, Mitchell K, McQuain C, Campbell CL, Guardiani R, Wuu J, Ollari C, Reale F, Nelson BE, Chen A et al (2001) Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. Cancer Lett 162:105–115

[23] Semerad CL, Poursine-Laurent J, Liu F, Link DC (1999) A role for G-CSF receptor signaling in the regulation of hematopoietic cell function but not lineage commitment or differentiation. Immunity 11:153–161

[24] Semerad CL, Liu F, Gregory AD, Stumpf K, Link DC(2002)G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity 17:413–423

[25] Thevenot PT, Sierra RA, Raber PL, Al-Khami AA, Trillo-Tinoco J, Zarreii P, Ochoa AC, Cui Y, DelValle L, Rodriguez PC (2014)The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity 41:389–401

[26] Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789–799

[27] von Vietinghoff S, Asagiri M, Azar D, Hoffmann A, Ley K (2010) Defective regulation of CXCR2 facilitates neutrophil release from bone marrow causing spontaneous inflammation in severely NF-kappa B-deficient mice. J Immunol 185:670–678

[28] Waight JD, Hu Q, Miller A, Liu S, Abrams SI (2011) Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 6:e27690

[29] Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108–1113

[30] Yokoyama T, Hyodo M, Hosoya Y, Koinuma K, Kurashina K, Saitoh S, Hirashima Y, Arai W, Zuiki T, Yasuda Y et al (2005) Aggressive G-CSF-producing gastric cancer complicated by lung and brain abscesses, mimicking metastases. Gastric Cancer 8:198–201

[31] Youn JI, Nagaraj S, Collazo M, Gabrilovich DI (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181:5791–5802

RIGHTS & PERMISSIONS

2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.